SAN FRANCISCO--(BUSINESS WIRE)--
Audentes Therapeutics, Inc. (BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in December:
31st Annual Piper Jaffray Healthcare Conference
Fireside Chat: Tuesday, December 3, 2019, at 10:00am ET
New York, New York
2nd Annual Evercore ISI HealthCONx
Panel: “Gene Therapy Manufacturing Powerhouses,” Wednesday, December 4, 2019, at 8:45am ET
To access the live webcast of the Piper Jaffray fireside chat, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following the conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days. There is no webcast available for the Gene Therapy Manufacutring Powerhouses panel at the Evercore ISI HealthCONx conference.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. We are leveraging our AAV gene therapy technology platform and proprietary manufacturing expertise to develop programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown. Our product candidates are showing promising therapeutic profiles in clinical and preclinical studies across a range of neuromuscular diseases. Audentes is a focused, experienced and passionate team driven by the goal of improving the lives of patients.
For more information regarding Audentes, please visit www.audentestx.com.